This preprint asked whether inherited genetic risk adds to prostate-specific antigen (PSA) for prostate cancer early detection. The P-CARE score, combining 601 variants, family history and ancestry, was tested in 428,512 Million Veteran Program men. High versus low P-CARE risk gave a hazard ratio of 3.32 for both treatment and metastasis. Men aged 40-49 with PSA 1-3 ng/mL had 15-year treatment or metastasis risks of 2.6%, 4.5% and 10.2% by group. It also predicted clinically significant cancer on biopsy (odds ratio 2.96), and results held in the Prostate Cancer Prevention Trial. The study is observational and the score has not been tested in a prospective screening programme.
Why it is interesting: In men aged 40-49 with PSA 1-3 ng/mL, 15-year treatment or metastasis probability was 10.2% at high P-CARE risk. It was 2.6% at low risk, and findings held in a separate trial.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.